1. Cyclooxygenase-2 Inhibitors in Human Skeletal Fracture Healing
- Author
-
Aaron Daluiski, Mathias P.G. Bostrom, Bryan J. Nestor, Dietrich A. Stephan, Robert N. Hotchkiss, Yuexian Shi, Keri E. Ramsey, and George Martin
- Subjects
Adult ,Male ,musculoskeletal diseases ,medicine.medical_specialty ,Nonunion ,Bone Morphogenetic Protein 2 ,Bone healing ,Cell Line ,Immune system ,Osteogenesis ,Transforming Growth Factor beta ,Internal medicine ,medicine ,Humans ,Cyclooxygenase Inhibitors ,Orthopedics and Sports Medicine ,Bony Callus ,Aged ,Aged, 80 and over ,Fracture Healing ,Sulfonamides ,biology ,business.industry ,Membrane Proteins ,Middle Aged ,medicine.disease ,Recombinant Proteins ,Gene expression profiling ,Endocrinology ,Celecoxib ,Cyclooxygenase 2 ,Cell culture ,Fractures, Ununited ,Bone Morphogenetic Proteins ,Orthopedic surgery ,Cancer research ,biology.protein ,Pyrazoles ,Female ,Surgery ,Cyclooxygenase ,business ,medicine.drug - Abstract
This article identifies the underlying molecular events responsible for fracture nonunions in a subset of fracture patients. Expression profiling of fracture callus tissue from both uneventful fracture repair and nonunion outcomes showed a decrease of COX-2 expression and an inability to mount an immune response in nonunion fractures. Validation in vitro with Saos-2 osteoprogenitor cell lines showed a decrease in osteogenesis potential after the cells were treated with celecoxib, a COX-2 specific inhibitor and anti-inflammatory agent. This article recapitulates that an initial immune response is crucial to fracture healing and suggests limited usage of COX-2 inhibitors in patients with healing fractures.
- Published
- 2006
- Full Text
- View/download PDF